DMAAU Drugs Made In America Acquisition Corp. - Units

NAS · US · Financial Services · Shell Companies

10.99USD0.00%Mkt Cap: —P/E: —6d ago

Drugs Made In America Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business …

Industry Peers

Shell Companies

Armada Acquisition Corp. II

$790.07MUSDP/E 227.4

DMII

Drugs Made In America Acquisition II Corp.

$649.10MUSDP/E 34.0

CCXI

Churchill Capital Corp XI

$626.07MUSD

EVAC

EQV Ventures Acquisition Corp. II

$602.60MUSDP/E 34.4

BCSS

Bain Capital GSS Investment Cor

$596.85MUSD

CXII

Churchill Capital Corp XII

$591.61MUSD

CEPF

Cantor Equity Partners IV, Inc.

$586.93MUSDP/E 31.1

AC8

Intuitive Investments Group Plc

$532.06MUSDP/E 2.5

AEXA

American Exceptionalism Acquisition Corp. A

$536.65MUSD

NWAX

New America Acquisition I Corp.

$500.24MUSD

AAC

Ares Acquisition Corporation III

$496.66MUSD

MLAA

Mountain Lake Acquisition Corp. II

$490.34MUSD

KRSP

Rice Acquisition Corporation 3

$486.71MUSD

BRTM

B&R Technology Merger Corp.

$478.69MUSD

CRAN

Crane Harbor Acquisition Corp. II

$473.69MUSD

GTEN

Gores Holdings X, Inc.

$470.58MUSDP/E 21.3

GCGR

General Catalyst Global Resilience Merger Corp.

$467.87MUSD

APXT

Apex Treasury Corporation

$466.49MUSD

BCCQ

Bleichroeder Acquisition Corp. III

$457.24MUSD

Key Statistics

Company

Market Cap—

Enterprise Value267.13M USD

Revenue (TTM)—

Gross Profit—

Net Income (TTM)5.94M USD

Revenue/Share—

Last Price10.99 USD

Fiscal Year EndDec 2025

MR QuarterJun 2026

Employees—

CountryUS

SectorFinancial Services

IndustryShell Companies

ISIN—

Valuation

P/E (Trailing)—

P/E (Forward)—

PEG—

EV/EBITDA—

EV/Revenue—

P/S—

P/B-35.38

EPS (TTM)—

EPS (Forward)—

52W Range

10.3031% of range12.50

52W High12.50 USD

52W Low10.30 USD

Profitability

Gross Margin0.00%

Oper. Margin0.00%

EBITDA Margin0.00%

Profit Margin0.00%

ROE2.55%

ROA2.48%

Growth

Revenue Growth—

Earnings Growth-17.90%

Cash Flow & Leverage

Operating CF-539.19K USD

CapEx (TTM)—

FCF Margin—

FCF Yield—

Net Debt329.72K USD

Net Debt/EBITDA—

Balance Sheet

Debt/Equity—

Current Ratio0.02

Quick Ratio0.01

Book Value/Sh-0.30 USD

Cash/Share0.0010 USD

Dividends

Fwd Div Rate—

Trail. Div Rate0.00 USD

Div. Yield0.00%

5Y Avg Yield—

Payout Ratio—

Ex-Div Date—

Pay Date—

Analyst Consensus

Rating—

Target (Mean)—

Target Range—

# Analysts—

Ownership

Shares Out.29.17M

Float19.79M

Insiders17.88%

Institutions1.54%

Short Interest

Short Ratio0.0d

Shares Short1

Short (prev mo.)1

Technical

SMA 5010.86 (+1.2%)

SMA 20010.69 (+2.8%)

Beta—

S&P 52W Chg15.78%

Avg Vol (30d)3

Avg Vol (10d)0

Technical Indicators

RSI (14)88.5

MACD0.0503

MACD Signal0.0388

MACD Hist.+0.0115

BB Upper11.10 USD

BB Middle10.89 USD

BB Lower10.68 USD

BB Width3.77%

ATR (14)0.0096 USD

Vol Ratio (20d)0.00x